WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of Nancy C. Andrews, M.D., Ph.D., to its Board of Directors, effective February 28, 2020. Dr. Andrews is Duke University’s Dean Emerita of its School of Medicine, Vice Chancellor Emerita for Academic Affairs, and Professor of Pediatrics, Pharmacology, and Cancer Biology. She is also on the Board of Directors of Novartis AG. Dr. Andrews’s extensive experience as a physician, scientist, professor, and senior administrator at leading academic institutions and hospitals will enhance the scientific leadership of Charles River’s Board of Directors. As a member of the Board, she will serve on the Science and Technology Committee and the Corporate Governance and Nominating Committee.
“Dr. Nancy Andrews is an accomplished administrator, educator, and researcher. Her experience overseeing prominent scientific research organizations will provide a unique client perspective to Charles River’s Board of Directors,” said James C. Foster, Chairman, President and Chief Executive Officer of Charles River. “Dr. Andrews’s extensive expertise in oncology, pharmacology, and pediatric research will strengthen our Board’s scientific knowledge, and her understanding of the research and development process will enable us to enhance our position as the partner of choice for our clients’ early-stage drug development programs. We look forward to working with Nancy and welcome her contributions to the continued, long-term success of Charles River.”
Dr. Andrews’s distinguished career spans more than 30 years and has culminated in leadership roles at two of the premier medical schools in the United States. Her tireless support of research and faculty development and her commitment to diversity and inclusion have been hallmarks of Dr. Andrews’s notable career. Prior to joining Duke University in 2007, Dr. Andrews served as Dean for Basic Sciences and Graduate Studies and the George Richards Minot Professor of Pediatrics at the Harvard Medical School, as well as Director of the Harvard-MIT M.D.-Ph.D. Program. She was also a biomedical research investigator at the Howard Hughes Medical Institute. In addition to Novartis’s Board, Dr. Andrews is also on the Executive Committee of the MIT Corporation; Chair of the Board of Directors of the American Academy of Arts and Sciences; and on the Scientific Advisory Board of Dyne Therapeutics. Dr. Andrews received an M.D. degree from Harvard Medical School, a Ph.D. degree in Biology from Massachusetts Institute of Technology, and B.S. and M.S. degrees in Molecular Biophysics and Biochemistry from Yale University.
“I am very pleased to join Charles River’s Board of Directors and look forward to helping guide the Company through the next stage of growth and development,” said Dr. Andrews. “Throughout my career, I have recognized the value of Charles River’s extensive scientific expertise and deep commitment to its clients. I am excited to use my experience in science and medicine to help shape the future success of this recognized global leader in early-stage drug research and development.”
Caution Concerning Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “intend,” “will,” “may,” “estimate,” “plan,” “outlook,” and “project,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward looking statements include statements in this press release regarding the specific contributions of members of Charles River's Board of Directors. Forward-looking statements are based on Charles River’s current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River’s Annual Report on Form 10-K as filed on February 11, 2020, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this press release except as required by law.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.